Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny study tests diuretics for dialysis patients – terminated early

NCT ID NCT05915286

Disease control Sponsor: University of Alberta Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested two diuretics (furosemide and chlorthalidone) in people on dialysis who still had some kidney function. The goal was to see if these water pills could help preserve remaining kidney function, increase urine output, and reduce weight gain between dialysis sessions. Only 2 participants were enrolled, and the study was terminated early, so no firm conclusions can be drawn.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Furosemide and chlorthalidone (water pills)
What this could lead to
If it works, this could point toward a way to help dialysis patients keep some kidney function and reduce fluid buildup between treatments.
What could go wrong
This was a very small pilot study (only 2 participants) that was terminated early, so results are not reliable. It is too early to know if diuretics are safe or effective for dialysis patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

2 people

The number who actually took part.

Started

May 2023

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients (age 18 years or older), who are within their first 12 months of chronic (expected to need dialysis for at least 6 months), in-centre hemodialysis therapy, and * Residual renal function defined as 24-hour urine volume \>200cc, and * Life expectancy of at least 6 months, and * Participants must be able to understand the consent process and be able to sign a consent form or have a substitute decision maker who is able to understand and sign consent on their behalf. In the case of non-English speaking participants, a translator service will be used to provide study information and obtain consent. Exclusion Criteria: * Unable to complete baseline urine collection * Documented allergy or adverse reaction to furosemide or chlorthalidone. * Unable to take oral medications * Patients expecting to change modality (peritoneal dialysis, home dialysis) or to receive a renal transplant in the next 6 weeks * History of hypokalemia (\<3.0 mmol/L), hypomagnesemia (\<0.6mmol/L), or hypocalcaemia (\<1.9mmol/L) in preceding 2 weeks. * Already participating in another study and one of the studies could interfere with the other study * Use of loop, or thiazide diuretic medications in the last week (if a patient is on chronic diuretics, they would need to be discontinued for 1 week before starting the trial)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End stage renal disease on dialysis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

End stage renal disease on dialysis

Contacts and locations

Locations

  • University of Alberta

    Edmonton, Alberta, T6G 2B7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.